Galmed Pharmaceuticals Ltd. (GLMD) 7.13 $GLMD
Galmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies
PR Newswire - Mon Apr 28, 4:57PM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that it commenced patient screening for pharmacokinetic, or PK, and food effect studies of aramchol. In written correspondence regarding a requested pre-Investigational New Drug application meeting, the U.S. Food and Drug Administration recommended that Galmed conduct such studies prior to commencing its planned Phase IIb clinical trial of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH, in obese patients with insulin resistance.
Leading Companies Being Defined in the Hunt for a NASH Treatment
ACCESSWIRE - Thu Mar 27, 9:32AM CDT
March 27, 2014 / The race to develop a treatment for Non-Alcoholic Steatohepatitis (NASH) is getting a lot of airtime lately, pointing to the severity of the disease, poor prognosis and desperate need for a treatment. The space has only a handful of competitors, with most seeing rising valuations due to the tremendous peak sales that analysts are projecting for products that make it to market. What is particularly unique to this disease is not only the lack of any approved treatments, but also the influx of attention and growing broad body of research by companies like Intercept Pharmaceuticals (NASDAQ: ICPT), Galmed Pharmaceuticals (NASDAQ: GLMD) and Galectin Therapeutics (NASDAQ: GALT) that shows treatments are on the horizon, which gives these equities considerable upside.
Galmed Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Tue Mar 18, 10:40AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" today announced the closing of its initial public offering of 3,263,010 ordinary shares at a public offering price of $13.50 per share, which included 425,610 ordinary shares issued upon the exercise in full of the underwriters' option to purchase additional ordinary shares to cover over-allotments. The aggregate gross proceeds from the sale of the shares were approximately $44.1 million, before deducting underwriting discounts, commissions and other estimated offering expenses. The net proceeds from the sale of the shares, after deducting underwriting discounts, commissions and other estimated offering expenses were approximately $39.7 million. The ordinary shares issued in the offering are listed on the NASDAQ Capital Market under the trading symbol "GLMD."
Galmed Pharmaceuticals Announces Pricing of Initial Public Offering
PR Newswire - Wed Mar 12, 7:07PM CDT
Galmed Pharmaceuticals Ltd. ("Galmed" today announced the pricing of its initial public offering of 2,837,400 ordinary shares at a public offering price of $13.50 per share, before underwriting discounts and commissions. Galmed has granted the underwriters an option for a period of 45 days to purchase, at the public offering price less the underwriting discount, up to 425,610 additional ordinary shares to cover over-allotments. The shares to be issued in the offering have been approved for listing on the NASDAQ Capital Market and are expected to begin trading under the ticker symbol "GLMD" on March 13, 2014.
Galmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies
PR Newswire - Mon Apr 28, 4:57PM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
, a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, announced today that it commenced patient screening for pharmacokinetic, or PK, and food effect studies of aramchol. In written correspondence regarding a requested pre-Investigational New Drug application meeting, the U.S. Food and Drug Administration recommended that Galmed conduct such studies prior to commencing its planned Phase IIb clinical trial of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH, in obese patients with insulin resistance. Leading Companies Being Defined in the Hunt for a NASH Treatment
ACCESSWIRE - Thu Mar 27, 9:32AM CDT
March 27, 2014 / The race to develop a treatment for Non-Alcoholic Steatohepatitis (NASH) is getting a lot of airtime lately, pointing to the severity of the disease, poor prognosis and desperate need for a treatment. The space has only a handful of competitors, with most seeing rising valuations due to the tremendous peak sales that analysts are projecting for products that make it to market. What is particularly unique to this disease is not only the lack of any approved treatments, but also the influx of attention and growing broad body of research by companies like Intercept Pharmaceuticals (NASDAQ: ICPT), Galmed Pharmaceuticals (NASDAQ: GLMD) and Galectin Therapeutics (NASDAQ: GALT) that shows treatments are on the horizon, which gives these equities considerable upside.
Galmed Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Tue Mar 18, 10:40AM CDT
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"
today announced the closing of its initial public offering of 3,263,010 ordinary shares at a public offering price of $13.50 per share, which included 425,610 ordinary shares issued upon the exercise in full of the underwriters' option to purchase additional ordinary shares to cover over-allotments. The aggregate gross proceeds from the sale of the shares were approximately $44.1 million, before deducting underwriting discounts, commissions and other estimated offering expenses. The net proceeds from the sale of the shares, after deducting underwriting discounts, commissions and other estimated offering expenses were approximately $39.7 million. The ordinary shares issued in the offering are listed on the NASDAQ Capital Market under the trading symbol "GLMD." Galmed Pharmaceuticals Announces Pricing of Initial Public Offering
PR Newswire - Wed Mar 12, 7:07PM CDT
Galmed Pharmaceuticals Ltd. ("Galmed"
today announced the pricing of its initial public offering of 2,837,400 ordinary shares at a public offering price of $13.50 per share, before underwriting discounts and commissions. Galmed has granted the underwriters an option for a period of 45 days to purchase, at the public offering price less the underwriting discount, up to 425,610 additional ordinary shares to cover over-allotments. The shares to be issued in the offering have been approved for listing on the NASDAQ Capital Market and are expected to begin trading under the ticker symbol "GLMD" on March 13, 2014. 
